ClinicalTrials.gg
RecruitingNCT06113848Updated Nov 2, 2023

Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy

A Phase 3 interventional study of Intra-Arterial TNK and Albumin and Intra-Arterial TNK in Acute Ischemic Stroke, sponsored by Tianjin Huanhu Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Tianjin Huanhu Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.

Started
2023
with 2 others
Phase 3
Only one
of the 12
Primary completion
2024-09
later than 2 of 10 live
Registered
4th of 12
by date

Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is one of 3 that started in 2023, is the only one in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 4th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the feasibility and efficacy of intra-arterial TNK and albumin for patients with acute ischemic stroke after successful thrombectomy and whether there is a synergistic effect between TNK and albumin.

Read the detailed description

Endovascular therapy is the first-line treatment for acute ischemic stroke with large vessel occlusion. However, many studies have shown that, even with successful recanalization, about half of patients do not achieve functional independence. This phenomenon is called futile recanalization, which is partly attributed to brain no-reflow (microcirculation reperfusion failure despite recanalization of the occluded large artery). The mechanisms of brain no-reflow phenomenon include inflammation, micro thrombosis, aggregation platelets and red blood cells, and pericyte contraction.

Albumin, the most copious plasma protein synthesized primarily in the liver, possesses various biochemical properties, including anti-inflammatory, inhibiting platelet aggregation and micro thrombosis formation, and increasing microvascular perfusion. All of these properties are directed toward the mechanisms of no-reflow production, so albumin may inhibit no-reflow to improve the prognosis of stroke patients. TNK is a new generation thrombolytic agent that inhibits thrombosis, improves microcirculatory perfusion, and may inhibit no-reflow. These functions of TNK are similar to those of albumin, and the two also can reduce infraction volume and cerebral edema, and improve of behavioral function. In this study, we plan to determine the feasibility and efficacy of intra-arterial TNK and albumin for stroke patients undergoing successful mechanical thrombectomy and whether there is a synergistic effect between TNK and albumin.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute ischemic stroke
  • Albumin
  • TNK
  • No-reflow
  • Endovascular Therapy
  • Large Vessel Occlusion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. AIS patients with large vessel occlusion;
  2. Age between 18 and 80 years;
  3. Baseline NIHSS score ≥ 6; 4 .Successful recanalization after thrombectomy (mTICI grades ≥ 2b);
  1. ASPECTS score ≥ 6 on CT; 6. First episode or previous episode without significant sequelae (mRS ≤ 2); 7. Time from onset to femoral artery puncture ≤ 24 hours; 8. Written provided by the patients or their legal relatives.

Exclusion criteria

Exclusion criteria:

  1. Upon admission, the patient's medical history and physical examination revealed manifestations indicative of congestive heart failure (CHF), such as jugular venous distention, the presence of a third heart sound, resting tachycardia at a rate of 100 beats per minute attributable to heart failure, hepatomegaly, and/or lower extremity edema attributable to heart failure or of unknown etiology;
  2. History of acute myocardial infarction within the preceding 3 months;
  3. The patient's medical history, findings upon admission, or physical examination indicated the presence of second- or third-degree heart block or any arrhythmia associated with hemodynamic instability, as determined by the investigator's assessment;
  4. Acute or chronic renal failure with serum creatinine levels exceeding 2.0 mg/dL;
  5. Severe anemia characterized by a hematocrit below 32%;
  6. Computed tomography findings upon admission indicating the presence of any form of hemorrhage;
  7. Pregnancy status;
  8. Previous history of allergic reactions to albumin administration or TNK administration;
  9. Elevated blood pressure exceeding 185/110 mmHg when investigating the use of albumin administration or TNK administration;
  10. Presence of other potentially life-threatening medical conditions;
  11. Individuals with current chronic lung diseases, such as , bronchiectasis, or any other lung disorder that significantly impairs daily activities;
  12. Individuals with known allergies to albumin or TNK;
  13. Patients with reocclusion within 24 hours;
  14. Clinical suspicion of aortic coarctation、 bacterial embolism and infective endocarditis;
  15. Patients with a history of coagulation disorders and systemic bleeding tendencies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Intra-Arterial TNK and Albumin

    Drug: Intra-Arterial TNK and Albumin

  • Active comparator
    Intra-Arterial TNK

    Drug: Intra-Arterial TNK

  • Active comparator
    Intra-Arterial Albumin

    Drug: Intra-Arterial Albumin

  • Sham comparator
    sham

    Other: sham

Interventions

  • DrugIntra-Arterial TNK and Albumin

    The study population was divided into four groups, one of which had intra-arterial TNK and albumin.

  • DrugIntra-Arterial TNK

    The study population was divided into four groups, one of which had intra-arterial TNK .

  • DrugIntra-Arterial Albumin

    The study population was divided into four groups, one of which had intra-arterial albumin.

  • Othersham

    The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.

06

What researchers measure

Primary outcomes

  1. Number of participants with major response

    Major response is any of the following: 1. Any forms of intracranial hemorrhage; 2. Pulmonary edema; 3. Heart failure; 4. Skin itching, dyspnea and other allergic reactions; 5. Death of any causes.

    Time frame: 7 days after initiation of TNK or albumin intra-arterially

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2024, 12 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 2, 2023
StartActual
Sep 7, 2023
Primary completionEst.
Sep 7, 2024
CompletionEst.
Sep 7, 2024
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06113848
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Ming Wei (Chief Physician, Tianjin Huanhu Hospital) — Principal investigator
First posted
Nov 2, 2023
Start date
Sep 7, 2023
Primary completion
Sep 7, 2024 (estimated)
Completion
Sep 7, 2024 (estimated)
Last update
Nov 2, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion